Latest Breaking News On - Brazilian health regulator - Page 1 : comparemela.com
Президент Бразилии Жаир Болсонару дал положительный результат на COVID
rusplt.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rusplt.ru Daily Mail and Mail on Sunday newspapers.
Кто и почему агитировал в Абхазии за справедливоросса Юрия Григорьева?
ekhokavkaza.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ekhokavkaza.com Daily Mail and Mail on Sunday newspapers.
COVID-19 vaccine: Brazil rejects import of Russia s Sputnik V; cites inherent risks, serious defects
Anvisa s five-strong board voted unanimously not to approve the Russian vaccine after technical staff had highlighted inherent risks and serious defects, citing a lack of information guaranteeing its safety, quality and effectiveness
Reuters | April 27, 2021 | Updated 14:33 IST
The Brazilian health regulator Anvisa on Monday rejected importing the Russian-made Sputnik V Covid-19 vaccine requested by state governors battling a deadly second wave of the virus that is battering Latin America s largest nation. Anvisa s five-strong board voted unanimously not to approve the Russian vaccine after technical staff had highlighted inherent risks and serious defects, citing a lack of information guaranteeing its safety, quality and effectiveness.
URL copied
Brazil says no to Russia s Sputnik V
The Brazil National Health Surveillance Agency (Anvisa)Â declined the request to approve the Russian-developed Sputnik V vaccine against COVID-19 for emergency use in Brazil. While, emergency use of COVID-19 vaccines from Chinaâs Sinovac Biotech Ltd and Britainâs AstraZeneca have been approved by the regulator.Â
Citing the agency, TASS reported that the request does not comply with the minimal criteria for this task. The request was returned to Uniao Quimica, because it does not comply with the minimal criteria in particular, due to lack of permission for third phase of clinical trials, as well as in regards to issue dealing with the advanced production methods, TASS quoted the Anivsa.